[Clinical evaluation of amoxicillin sustained-release preparation in urinary tract infection].
C-AMOX, a new prolonged acting preparation of amoxicillin was administered to 122 cases by oral administration of daily dosage 500 mg twice. Clinical effectiveness of C-AMOX was evaluated in 115 out of 122 cases (acute simple cystitis 87 cases, acute pyelonephritis 6 cases, complicated urinary tract infection 19 cases and others 3 cases), and the following results were obtained. 1. The clinical effect for 87 cases of acute simple cystitis was excellent in 54 cases (62%), moderate in 24 cases (27.6%) and poor 9 cases (10.3%), overall effective rate being 89.7%. 2. The clinical effect for 19 cases of complicated urinary tract infection was excellent in 6 cases (31.6%), good 8 cases (42.1%) and poor 5 cases (26.3%), overall effective rate being 73.7%. 3. Adverse reaction occurred in 2 patients, one gastric discomfort and the other one slight diarrhoea. No laboratory abnormalities attributable to C-AMOX were observed in the present study.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000658:Amoxicillin / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology; D001419:Bacteria / Q000187:drug effects; D003692:Delayed-Action Preparations; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010403:Penicillin Resistance; D014552:Urinary Tract Infections / Q000188:drug therapy*
D003692:Delayed-Action Preparations; D000658:Amoxicillin